Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A retrospective multicenter study
Conclusion
Overall, our data confirm the efficacy of lenvatinib as first-line treatment and did not revea l new or unexpected side effects in a large retrospective Caucasian real-world cohort, supporting the use of lenvatinib as meaningful alternative for patients that cannot be treated with IO-based combinations in first-line HCC.
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Austria Health | Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Germany Health | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology